Venetoclax Combinations Show Promise Across ALL/AML

Venetoclax-based regimens are delivering meaningful response rates and deep molecular remissions in patients with newly diagnosed acute leukemia, even in subtypes where treatment options have historically been limited, according to 2 poster presentations at the recent European Hematology Association 2026 Congress.^1,2

Although focused on distinct diagnoses—T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML) in younger adults—the studies converged on a shared conclusion: Adding venetoclax, a selective B-cell lymphoma 2 (BCL-2) inhibitor, to established chemotherapy or hypomethylating backbones drives high complete remission rates, frequent measurable residual disease (MRD) negativity, and a viable path to transplant. Together, they reflect a broadening clinical consensus that BCL-2 inhibition may reshape frontline treatment strategy across leukemia subtypes, not just in the older or unfit patients among whom venetoclax first gained traction.

Venetoclax Plus Chemotherapy in Newly Diagnosed Adult T-ALL¹

Adult T-ALL remains one of the more treatment-resistant hematologic malignancies, with suboptimal outcomes under conventional intensive chemotherapy and limited prospective data on BCL-2 inhibition in newly diagnosed disease. This first poster reported interim results from an ongoing multicenter phase 2 trial evaluating venetoclax combined with a pediatric-inspired chemotherapy regimen in adults with newly diagnosed T-ALL.

Of 27 patients enrolled between August 2024 and December 2025, 23 were evaluable at the time of analysis. The median age was 34 years, 65.2% were male patients, and 47.8% had early T-cell precursor ALL (ETP-ALL), a particularly aggressive subtype. The overall response rate after 1 induction cycle was 87% (n = 20 patients), with comparable responses across ETP-ALL (90.9%) and non–ETP-ALL (83.3%). Among patients achieving complete remission, the MRD-negative rate was 75%, including 70% in ETP-ALL and 80% in non–ETP-ALL.

The safety profile was consistent with known chemotherapy toxicities: Leukocytopenia and thrombocytopenia occurred in all patients, with median times to platelet and neutrophil recovery of 22 and 21 days, respectively. Tumor lysis syndrome was rare; it was only seen in 1 patient and resolved with supportive care. No early deaths were reported. Twelve patients (52.2%) proceeded to allogeneic stem cell transplantation.

The investigators concluded that venetoclax-based combinations could enhance the efficacy of intensive chemotherapy in T-ALL, with particular benefit in the ETP-ALL subgroup.

HMAs Plus Venetoclax in Younger AML²

Although hypomethylating agents (HMAs) combined with venetoclax have become a standard of care for older or unfit patients with AML, their application in younger patients has been less systematically studied. The second poster, presented by a team from Italian academic medical centers, reported results from a systematic review and meta-analysis of the HMA-venetoclax (HMA/Ven) combination in AML patients under age 70, conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered in the international database.

The analysis pooled data from 56 records, ultimately including 8 studies; there were 5 randomized controlled trials, 2 prospective phase 2 trials, and 1 real-world study comprising 673 patients with a median age of 54 years. The pooled complete response rate was 41% to 49%, with moderate heterogeneity. The pooled 1-year overall survival was approximately 75%, and MRD negativity was achieved in close to 50% of evaluable patients. Notably, approximately 75% of patients across 5 contributing studies proceeded to allogeneic hematopoietic stem cell transplantation, suggesting HMA/Ven may serve as an effective bridge to transplant in this population. The meta-regression pointed to patient age and HMA backbone, azacitidine vs decitabine, as factors influencing event-free survival outcomes, although direct comparisons were limited by between-study heterogeneity.

The authors concluded that HMA/Ven demonstrates a favorable efficacy-toxicity profile in younger patients with AML and called for prospective trials to define optimal dosing, sequencing, and the combination’s role relative to intensive chemotherapy.

Taken together, these posters point toward a broader repositioning of venetoclax from a tool reserved for patients unable to tolerate intensive therapy to a partner in frontline regimens targeting deep remission and transplant eligibility across a wider range of leukemia diagnoses. Further survival data from both studies, and the results of prospective trials now enrolling, will be closely watched by the managed care and hematology communities.

References

1. Peng LJ, Liu WY, Ren JY, et al. Combination of venetoclax and chemotherapy in newly diagnosed adult T-cell acute lymphoblastic leukemia: interim analysis of a multicenter prospective study. Presented at: EHA 2026; June 11-14, 2026; Stockholm, Sweden. Poster PS1476.
2. Molica M, De Fazio L, Monachetti S, Rossi M, Perrone S. Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: meta-analysis of a shifting treatment paradigm. Presented at: EHA 2026; June 11-14, 2026; Stockholm, Sweden. Poster PF510.